

AMENDMENTS

Please enter the following amendments without prejudice or disclaimer.

In the claims:

Please cancel claims 7, 18, 41, 42 and 43.

Please amend claims 1, 4-6, 8, 11, 15, 16 and 37-39 as follows.

B2 1. (Amended) A method for providing dopamine or a dopamine precursor to a subject with schizophrenia, comprising administering a cell/support complex to the prefrontal cortex of the subject's brain, wherein said cell/support complex comprises therapeutic cells adhered to a support matrix, wherein said therapeutic cells produce dopamine or a dopamine precursor and wherein said cell/support complex is administered in an amount effective to alleviate a negative symptom of schizophrenia.

B2 4. (Amended) The method of claim 1 wherein said support matrix is made of material selected from the group consisting of glass, polystyrene, polypropylene, polyethylene, polyvinylidene fluoride, polyurethane, polyalginate, polysulphone, polyvinyl alcohol, acrylonitrile polymers, polyacrylamide, polycarbonate, polypentene, polypentane, acrylonitrile polymer, nylon, magnetite, natural polysaccharide, modified polysaccharide, collagen, gelatin and modified gelatin.

5. (Amended) The method of claim 4, wherein said support matrix is gelatin or modified gelatin.

6. (Amended) The method of claim 5 wherein said support matrix is crosslinked gelatin.

B3 *80C3* 8. (Amended) The method of claim 1, wherein the therapeutic cells are selected from the group consisting of retinal pigment epithelial cells, chromaffin cells, cells of neural origin, paraneural cells, cells engineered by somatic cell hybridization, cells derived from the adrenal medulla, and cells that have been genetically engineered to express dopamine or a dopamine precursor.

B4 *80C3* 11. (Amended) The method according to claim 8 wherein the therapeutic cells are retinal pigment epithelium (RPE) cells.

B5 15. (Amended) The method of claim 1 wherein said cell/support complex further comprises protective cells adherent to a support matrix.

16. (Amended) The method of claim 15 wherein said cell/support complex further comprises support cells adherent to a support matrix.

80C4 37. (Amended) A pharmaceutical composition comprising therapeutic cells and Sertoli cells, wherein the cells are adhered to a support matrix.

B6 38. (Amended) A pharmaceutical composition comprising therapeutic cells, protective cells and support cells, wherein the cells are adhered to a support matrix.

39. (Amended) A kit suitable for use in providing dopamine or a dopamine precursor to a subject with schizophrenia, comprising in a suitable packaging:
therapeutic cells that produce dopamine or a dopamine precursor;
protective cells;
support cells; and
a support matrix, wherein the cells can be adhered to the support matrix.